title: Management of ruptured retinal arterial macroaneurysm with intravitreal bevacizumab.
abstract: The authors report the management of a ruptured retinal arterial macroaneurysm and associated hemorrhages with intravitreal injections of bevacizumab. A 79-year-old woman presented with a history of systemic arterial hypertension and a ruptured retinal arterial macroaneurysm with pre-retinal, intraretinal, and subretinal hemorrhages extending into the macula. Visual acuity at presentation was 20/400. The patient was treated with two intravitreal injections of bevacizumab at 4-week intervals. Steady clearing of the pre-retinal, intraretinal, and subretinal hemorrhages was observed with restoration of final visual acuity to 20/20 in the 12 months after the initial presentation. It appears that the novel application of intravitreal bevacizumab may be used in the treatment of ruptured retinal arterial macroaneurysm.
authors.affiliation: Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Palm Beach Gardens, Florida, USA.
authors.forename: Golnaz
authors.initials: G
authors.lastname: Javey
authors.forename: Arlanna N
authors.initials: AN
authors.lastname: Moshfeghi
authors.forename: Andrew A
authors.initials: AA
authors.lastname: Moshfeghi
mesh_terms: D000368:Aged; D017542:Aneurysm, Ruptured / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004334:Drug Administration Schedule; D005260:Female; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D012161:Retinal Artery; D012166:Retinal Hemorrhage / Q000209:etiology / Q000503:physiopathology; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014463:Ultrasonography; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab